Format
Sort by

Send to

Choose Destination

Search results

Items: 14

1.

IFNG rs1861494 polymorphism is associated with IBD disease severity and functional changes in both IFNG methylation and protein secretion.

Gonsky R, Deem RL, Landers CJ, Haritunians T, Yang S, Targan SR.

Inflamm Bowel Dis. 2014 Oct;20(10):1794-801. doi: 10.1097/MIB.0000000000000172.

2.

Markers of intestinal inflammation in patients with ankylosing spondylitis: a pilot study.

Matzkies FG, Targan SR, Berel D, Landers CJ, Reveille JD, McGovern DP, Weisman MH.

Arthritis Res Ther. 2012 Nov 29;14(6):R261. doi: 10.1186/ar4106.

3.

Combination of genetic and quantitative serological immune markers are associated with complicated Crohn's disease behavior.

Lichtenstein GR, Targan SR, Dubinsky MC, Rotter JI, Barken DM, Princen F, Carroll S, Brown M, Stachelski J, Chuang E, Landers CJ, Stempak JM, Singh S, Silverberg MS.

Inflamm Bowel Dis. 2011 Dec;17(12):2488-96. doi: 10.1002/ibd.21661. Epub 2011 Mar 9.

4.

Distinct IFNG methylation in a subset of ulcerative colitis patients based on reactivity to microbial antigens.

Gonsky R, Deem RL, Landers CJ, Derkowski CA, Berel D, McGovern DP, Targan SR.

Inflamm Bowel Dis. 2011 Jan;17(1):171-8. doi: 10.1002/ibd.21352.

5.

TL1A selectively enhances IL-12/IL-18-induced NK cell cytotoxicity against NK-resistant tumor targets.

Heidemann SC, Chavez V, Landers CJ, Kucharzik T, Prehn JL, Targan SR.

J Clin Immunol. 2010 Jul;30(4):531-8. doi: 10.1007/s10875-010-9382-9. Epub 2010 Mar 27.

6.

Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease.

Ippoliti A, Devlin S, Mei L, Yang H, Papadakis KA, Vasiliauskas EA, McGovern DP, Abreu MT, Melmed G, Shaye O, Enayati P, Chen G, Choi J, Taylor K, Landers CJ, Rotter JI, Targan SR.

Inflamm Bowel Dis. 2010 Aug;16(8):1279-85. doi: 10.1002/ibd.21196.

7.

Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study.

Mundwiler ML, Mei L, Landers CJ, Reveille JD, Targan S, Weisman MH.

Arthritis Res Ther. 2009;11(6):R177. doi: 10.1186/ar2866. Epub 2009 Nov 23.

8.

TLR8-mediated activation of human monocytes inhibits TL1A expression.

Saruta M, Michelsen KS, Thomas LS, Yu QT, Landers CJ, Targan SR.

Eur J Immunol. 2009 Aug;39(8):2195-202. doi: 10.1002/eji.200939216.

9.

IBD-associated TL1A gene (TNFSF15) haplotypes determine increased expression of TL1A protein.

Michelsen KS, Thomas LS, Taylor KD, Yu QT, Mei L, Landers CJ, Derkowski C, McGovern DP, Rotter JI, Targan SR.

PLoS One. 2009;4(3):e4719. doi: 10.1371/journal.pone.0004719. Epub 2009 Mar 5.

10.

Linkage of Crohn's disease-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBir1 and ASCA, and show reduced NF-kappaB activation.

Takedatsu H, Taylor KD, Mei L, McGovern DP, Landers CJ, Gonsky R, Cong Y, Vasiliauskas EA, Ippoliti A, Elson CO, Rotter JI, Targan SR.

Gut. 2009 Jan;58(1):60-7. doi: 10.1136/gut.2008.156422. Epub 2008 Oct 2.

11.

Enhanced CBir1-specific innate and adaptive immune responses in Crohn's disease.

Shen C, Landers CJ, Derkowski C, Elson CO, Targan SR.

Inflamm Bowel Dis. 2008 Dec;14(12):1641-51. doi: 10.1002/ibd.20645.

12.

TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation.

Takedatsu H, Michelsen KS, Wei B, Landers CJ, Thomas LS, Dhall D, Braun J, Targan SR.

Gastroenterology. 2008 Aug;135(2):552-67. doi: 10.1053/j.gastro.2008.04.037. Epub 2008 May 7.

13.

Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression.

Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S, Wrobel I, Quiros A, Vasiliauskas EA, Grill B, Israel D, Bahar R, Christie D, Wahbeh G, Silber G, Dallazadeh S, Shah P, Thomas D, Kelts D, Hershberg RM, Elson CO, Targan SR, Taylor KD, Rotter JI, Yang H; Western Regional Pediatric IBD Research Alliance.

Am J Gastroenterol. 2006 Feb;101(2):360-7.

14.

Bacterial flagellin is a dominant antigen in Crohn disease.

Lodes MJ, Cong Y, Elson CO, Mohamath R, Landers CJ, Targan SR, Fort M, Hershberg RM.

J Clin Invest. 2004 May;113(9):1296-306.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk